Cosmo Pharmaceuticals N.V. (CMOPF)

USD 55.0

(0.0%)

Operating Expenses Summary of Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V.'s latest annual operating expenses in 2023 was 47.29 Million EUR , up 57.5% from previous year.
Cosmo Pharmaceuticals N.V.'s latest quarterly operating expenses in 2024 Q1 was 13.64 Million USD , down -13.69% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a annual operating expenses of 34.14 Million USD in annual operating expenses 2022, up 59.69% from previous year.
Cosmo Pharmaceuticals N.V. reported a annual operating expenses of 21.38 Million USD in annual operating expenses 2021, down -45.26% from previous year.
Cosmo Pharmaceuticals N.V. reported a quarterly operating expenses of 13.64 Million USD for 2024 Q1, down -13.69% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a quarterly operating expenses of 19.91 Million USD for 2023 Q2, up 102.17% from previous quarter.

Annual Operating Expenses Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Operating Expenses of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Year	Operating Expenses	Operating Expenses Growth
2023	47.29 Million EUR	57.5%
2022	34.14 Million USD	59.69%
2021	21.38 Million USD	-45.26%
2020	39.06 Million USD	-32.65%
2019	58 Million USD	-18.89%
2018	71.52 Million EUR	13.47%
2017	63.03 Million EUR	145.79%
2016	25.64 Million EUR	-47.69%
2015	49.02 Million EUR	7.13%
2014	45.75 Million EUR	38.04%
2013	33.14 Million EUR	34.72%
2012	24.6 Million EUR	41.55%
2011	17.38 Million EUR	34.51%
2010	12.92 Million EUR	36.48%
2009	9.46 Million EUR	-3.25%
2008	9.78 Million EUR	8.9%
2007	8.98 Million EUR	23.05%
2006	7.3 Million EUR	-13.84%
2005	8.47 Million EUR	10.9%
2004	7.64 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	13.54 Million USD	3.37%
2024 Q1	13.64 Million USD	-13.69%
2023 Q2	19.91 Million USD	102.17%
2023 FY	53.78 Million USD	57.5%
2023 Q4	34.86 Million USD	125.2%
2023 Q3	15.48 Million USD	-22.24%
2023 Q1	9.84 Million USD	-48.81%
2022 FY	34.14 Million USD	59.69%
2022 Q4	19.24 Million USD	107.87%
2022 Q3	9.25 Million USD	-50.27%
2022 Q2	18.61 Million USD	0.0%
2021 FY	21.38 Million USD	-45.26%
2021 Q4	8.23 Million USD	0.0%
2021 Q2	17.49 Million USD	0.0%
2020 Q2	17.85 Million USD	0.0%
2020 FY	39.06 Million USD	-32.65%
2020 Q4	19.93 Million USD	0.0%
2019 Q4	25.51 Million USD	0.0%
2019 FY	58 Million USD	-18.89%
2019 Q2	32.38 Million USD	0.0%
2018 FY	71.52 Million EUR	13.47%
2017 FY	63.03 Million EUR	145.79%
2016 FY	25.64 Million EUR	-47.69%
2015 FY	49.02 Million EUR	7.13%
2014 FY	45.75 Million EUR	38.04%
2013 FY	33.14 Million EUR	34.72%
2012 FY	24.6 Million EUR	41.55%
2011 FY	17.38 Million EUR	34.51%
2010 FY	12.92 Million EUR	36.48%
2009 FY	9.46 Million EUR	-3.25%
2008 FY	9.78 Million EUR	8.9%
2007 FY	8.98 Million EUR	23.05%
2006 FY	7.3 Million EUR	-13.84%
2005 FY	8.47 Million EUR	10.9%
2004 FY	7.64 Million EUR	0.0%

Peer Operating Expenses Comparison of Cosmo Pharmaceuticals N.V.

Name	Operating Expenses	Operating Expenses Difference
AstraZeneca PLC	29.57 Billion USD	99.84%
Bristol-Myers Squibb Company PFD CONV 2	17.07 Billion USD	99.723%
CSPC Pharmaceutical Group Limited	2.14 Billion USD	97.797%
Clarus Therapeutics Holdings, Inc.	50.96 Million USD	7.21%
Novartis AG	24.87 Billion USD	99.81%
PT Kalbe Farma Tbk.	11823.24 Billion USD	100.0%